CG
VRTX icon

CFO4Life Group’s Vertex Pharmaceuticals VRTX Stock Holding History

CFO4Life Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,786
Closed -$837K – 227
2024
Q2 		$837K Buy
1,786
+12
+0.7% +$5.21K 0.16% 75
2024
Q1 		$742K Sell
1,774
-102
-5% -$43.1K 0.13% 88
2023
Q4 		$763K Sell
1,876
-95
-5% -$35.1K 0.15% 81
2023
Q3 		$685K Sell
1,971
-42
-2% -$14.7K 0.16% 76
2023
Q2 		$708K Buy
2,013
+106
+6% +$35.7K 0.15% 74
2023
Q1 		$601K Buy
1,907
+28
+1% +$8.4K 0.14% 86
2022
Q4 		$543K Buy
+1,879
New +$573K 0.12% 100

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CFO4Life Group's VRTX Position: Q3 2024 in Review

CFO4Life Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 1,786 shares — an estimated $837K sold.

CFO4Life Group first reported a position in VRTX in Q4 2022 and held it in 7 quarters. The position peaked at $837K in Q2 2024. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • CFO4Life Group reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • CFO4Life Group sold 1,786 Vertex Pharmaceuticals shares in Q3 2024, an estimated $837K.
  • CFO4Life Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • CFO4Life Group's Vertex Pharmaceuticals position peaked at $837K in Q2 2024.
  • 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on CFO4Life Group's 13F filing for Q3 2024, filed 12 Nov 2024.